SCHEMBL33525835

SCHEMBL33525835

COC(=O)C1CC[C@H]2CCCN2C1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 2/20 0.37
CYP1A2 P05177 1/20 0.37
HIF1A Q16665 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
OGFRL1 Q5TC84 1/20 0.35
ALDH1A1 P00352 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4515274 0.87 NPC1 (0.42) FKBP1ANPC1RAB9AKMT2ATP53
SCHEMBL33525767 0.78 NOS3 (0.36) KMT2AOPRM1OPRD1OPRK1OGFRL1
SCHEMBL5251126 0.75 CYP1A2 (0.39) FKBP1ACYP1A2HIF1ANPC1RAB9A
SCHEMBL13043822 0.75 CYP1A2 (0.44) FKBP1ACYP1A2HIF1ATP53SMN1; SMN2
SCHEMBL22978720 0.72 CYP1A2 (0.41) FKBP1ACYP1A2HIF1ATP53HSD17B10
SCHEMBL12053028 0.72 FPR2 (0.38) FKBP1ANPC1RAB9AKMT2A
SCHEMBL17527184 0.72 FPR2 (0.38) FKBP1ANPC1RAB9AKMT2A
SCHEMBL24603693 0.72 FPR2 (0.53) NPC1RAB9AKMT2ATP53ALDH1A1
SCHEMBL3105740 0.70 BRD4 (0.44) FKBP1ACYP1A2HIF1ATP53SMN1; SMN2
SCHEMBL19559460 0.70 MAPT (0.44) CYP1A2HIF1AKMT2ATP53HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600733-B2 KRAS inhibitors ELI LILLY AND COMPANY (US) 2026-04-14 US disclosed
US-20260092075-A1 KRAS INHIBITORS LILLY CO ELI (US) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600733-B2 KRAS inhibitors KRAS, NRAS, HRAS FKBP1A 4466/4885CYP1A2 3542/4885HIF1A 1950/4885
US-20260092075-A1 KRAS INHIBITORS KRAS, NRAS, HRAS FKBP1A 4352/4885CYP1A2 3258/4885HIF1A 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.